Study Of NMS-03305293 In Pts With Selected Advanced/Metastatic Solid Tumors

Study Overview

Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors

Phase I, first-in-human, open-label, multicenter, dose-escalation and dose expansion study with the aim of exploring safety, tolerability and preliminary antitumor activity of NMS-03305293 (a PARP inhibitor) as single agent in adult patients with selected advanced/metastatic, relapsed/refractory solid tumors who have exhausted standard treatment options or for whom standard therapy is considered unsuitable.

N/A

Advanced/Metastatic Solid Tumors

DRUG: NMS-03305293

PARPA-293-001
2018-003918-40 (EUDRACT_NUMBER Identifier) (EUDRACT_NUMBER: )

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2019-11-12	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2024-09-05
First Submitted that Met QC Criteria 2019-11-28	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ACTUAL) 2024-09-19
First Posted (ACTUAL) 2019-12-02	Results First Posted N/A	Last Verified 2024-09

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Non Randomized

Interventional Model:
Sequential

Masking:
None

Arms and Interventions

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Dose Escalation Part Patients with histologically confirmed diagnosis of locally advanced/metastatic HER2 negative breast cancer, epithelial ovarian cancer, castration-resistant prostate cancer (CRPC) or pancreatic cancer.	DRUG: NMS-03305293 All patients will receive NMS-03305293 administered orally on Days 1-21 (schedule A) or Days 1-28 (schedule B) in repeated 4-week cycles.
EXPERIMENTAL: Dose Expansion Part - Epithelial Ovarian Cancer Patients with gBRCA mutation and epithelial ovarian cancer.	DRUG: NMS-03305293 All patients will receive NMS-03305293 administered orally on Days 1-21 (schedule A) or Days 1-28 (schedule B) in repeated 4-week cycles.
EXPERIMENTAL: Dose Expansion Part - Pretreated HER 2 Neg. Breast Cancer Patients with gBRCA mutation and HER2 negative breast cancer previously treated with a PARP inhibitor.	DRUG: NMS-03305293 All patients will receive NMS-03305293 administered orally on Days 1-21 (schedule A) or Days 1-28 (schedule B) in repeated 4-week cycles.
EXPERIMENTAL: Dose Expansion Part - No Pretreated HER 2 Neg. Breast Cancer Patients with gBRCA mutation and HER2 negative breast cancer who have not received prior therapy with a PARP inhibitor.	DRUG: NMS-03305293 All patients will receive NMS-03305293 administered orally on Days 1-21 (schedule A) or Days 1-28 (schedule B) in repeated 4-week cycles.
EXPERIMENTAL: Dose Expansion Part - CRPC Patients with gBRCA mutation and castration-resistant prostate cancer (CRPC).	DRUG: NMS-03305293 All patients will receive NMS-03305293 administered orally on Days 1-21 (schedule A) or Days 1-28 (schedule B) in repeated 4-week cycles.
EXPERIMENTAL: Dose Expansion Part - Pancreatic Cancer Patients with gBRCA mutation and pancreatic cancer who have not received prior therapy with a PARP inhibitor.	DRUG: NMS-03305293 All patients will receive NMS-03305293 administered orally on Days 1-21 (schedule A) or Days 1-28 (schedule B) in repeated 4-week cycles.

Primary Outcome Measures	Measure Description	Time Frame
Number of Participants with first-cycle dose limiting toxicity		Time interval between the date of the first dose administration in Cycle 1 (each cycle is 28 days) and the date of the first dose administration in Cycle 2 which is expected to be 28 days or up to 42 days in case of dose delay due to toxicity

Secondary Outcome Measures	Measure Description	Time Frame
Number of participants with Adverse Events (AEs)	Safety will be assessed by AEs, which includes clinically significant abnormalities identified during a medical test (e.g. laboratory tests, vital signs, electrocardiogram, etc.). A treatment-emergent AE is defined as an AE observed after starting administration of the study drug up to 28 days after last dose of study medication intake. AEs will be coded with Medical Dictionary for Regulatory Activities and graded according to The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.	From the Informed Consent signature to 28 days after the last dose of study treatment administration.
Maximum concentration (Cmax) of NMS-03305293 after single and multiple doses of drug	Plasma samples will be collected and used for pharmacokinetics assessments.	Full PK : Schedule A, QD and BID dosing: Cycle 1, 2; Schedule B, QD and BID dosing: Cycle 1, 2 and 3. Sparse PK: Schedule A: and Schedule B Cycle 1, 2, 3 (last cycle and at each cycle from cycle 1 onwards).Cycle lenght is 4 weeks.
Time to observed Cmax (Tmax) of NMS-033052293 after single and multiple doses of drug	Plasma samples will be collected and used for pharmacokinetics assessments.	Full PK : Schedule A, QD and BID dosing: Cycle 1, 2; Schedule B, QD and BID dosing: Cycle 1, 2 and 3. Sparse PK: Schedule A: and Schedule B Cycle 1, 2, 3 (last cycle and at each cycle from cycle 1 onwards).Cycle lenght is 4 weeks.
Area under the concentration-time curve to the last of measurable concentration (AUClast) of NMS-033052293 after single and repeated dose of drug.	Plasma samples will be collected and used for pharmacokinetics assessments.	Full PK : Schedule A, QD and BID dosing: Cycle 1, 2; Schedule B, QD and BID dosing: Cycle 1, 2 and 3. Sparse PK: Schedule A: and Schedule B Cycle 1, 2, 3 (last cycle and at each cycle from cycle 1 onwards).Cycle lenght is 4 weeks.
Terminal elimination half-life (t1/2) of NMS-033052293 after single and multiple doses of drug.	Plasma samples will be collected and used for pharmacokinetics assessments.	Full PK : Schedule A, QD and BID dosing: Cycle 1, 2; Schedule B, QD and BID dosing: Cycle 1, 2 and 3. Sparse PK: Schedule A: and Schedule B Cycle 1, 2, 3 (last cycle and at each cycle from cycle 1 onwards).Cycle lenght is 4 weeks.
Area under the plasma concentration vs. time curve to infinity (AUCinf) of NMS-033052293 after multiple doses of drug.	Plasma samples will be collected and used for pharmacokinetics assessments.	Full PK : Schedule A, QD and BID dosing: Cycle 1, 2; Schedule B, QD and BID dosing: Cycle 1, 2 and 3. Sparse PK: Schedule A: and Schedule B Cycle 1, 2, 3 (last cycle and at each cycle from cycle 1 onwards).Cycle lenght is 4 weeks.
Accumulation ratio (Rac) of NMS-033052293 after multiple doses of drug.	Plasma samples will be collected and used for pharmacokinetics assessments.	Full PK : Schedule A, QD and BID dosing: Cycle 1, 2; Schedule B, QD and BID dosing: Cycle 1, 2 and 3. Sparse PK: Schedule A: and Schedule B Cycle 1, 2, 3 (last cycle and at each cycle from cycle 1 onwards).Cycle lenght is 4 weeks.
Oral plasma clearance (CL/F) of NMS-033052293 after multiple doses of drug.	Plasma samples will be collected and used for pharmacokinetics assessments.	Full PK : Schedule A, QD and BID dosing: Cycle 1, 2; Schedule B, QD and BID dosing: Cycle 1, 2 and 3. Sparse PK: Schedule A: and Schedule B Cycle 1, 2, 3 (last cycle and at each cycle from cycle 1 onwards).Cycle lenght is 4 weeks.
Apparent volume of distribution (Vd/F) of NMS-033052293 after multiple doses of drug.	Plasma samples will be collected and used for pharmacokinetics assessments.	Full PK : Schedule A, QD and BID dosing: Cycle 1, 2; Schedule B, QD and BID dosing: Cycle 1, 2 and 3. Sparse PK: Schedule A: and Schedule B Cycle 1, 2, 3 (last cycle and at each cycle from cycle 1 onwards).Cycle lenght is 4 weeks.
Renal clearance of NMS-033052293 after multiple doses of drug.	Samples of urine will be used for pharmacokinetics assessments. To be collected in all patients enrolled after the first DLT.	Schedule A, QD and BID dosing: Cycle 1 (Day 1 and 21). ; Schedule B, QD and BID dosing: Cycle 1 (Day 1 and 28).Cycle lenght is 4 weeks.
Objective tumor response (OR)	Objective tumor response (OR) measured using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. For prostate cancer patients response will be evaluated by RECIST version 1.1/PCWG3 for patients with measurable disease and by Prostatic Specific Antigen (PSA) for all patients through PCWG3 criteria.	At baseline, every even cycle (Day 28), at the end of treatment and at follow-up, every 8 weeks, till disease progression, an average 18 months.
Progression Free Survival (PFS)	Progression Free Survival (PFS) will be calculated from the date of treatment initiation to the date of first documentation of disease progression according to RECIST 1.1 or RECIST 1.1/PCWG3 for patient with CRPC, or death due to any cause, whichever comes first.	From date of first dose of study drug up to the date of first documentation of disease progression or death due to any cause, whichever comes first, an average of 2 years.
Time To Progression (TTP)	Time to Progression (TTP) will be evaluated from the date of treatment initiation to the date of first documentation of disease progression according to RECIST 1.1 criteria or RECIST 1.1/PCWG3 for patient with CRPC, or death due to progression, whichever comes first.	From date of first dose of study drug up to the date of first documentation of disease progression or death due to progression, an average of 2 years.
Time to PSA progression (for prostate cancer only)	Time to PSA Progression will be calculated from the date of treatment initiation to the date of first documentation of PSA progression according to PCWG3 criteria.	From date of first dose of study drug up to the date of first documentation of PSA progression, an average of 1 year.

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

PSA progression defined by a minimum of three rising PSA levels with an interval of ≥ 1 week between each determination. The PSA value at the Screening visit should be ≥ 2.0 ng/ml (µg/L). If the third PSA value is less than second PSA, a fourth PSA must be repeated and if the value is higher than second it must be considered as progressive disease;
Soft tissue/visceral disease progression defined by RECIST 1.1;
Bone disease progression defined by two or more new lesions on bone scan. 3. Male or female patients with age ≥ 18 years. 4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2. 5. Life expectancy of at least 3 months. 6. Signed and dated IEC or IRB-approved Informed Consent. 7. At least 4 weeks must have elapsed or, in absence of toxicity, 5 half-lives, since completion of prior cancer therapy (at least 6 weeks for nitrosureas, mitomycin C and liposomal doxorubicin) before Cycle 1 Day 1. 8. Prior platinum therapy is allowed provided that criteria for platinum refractory disease are not met (see exclusion criterion n.3). 9. Resolution of all acute toxic effects (excluding alopecia) of any prior anticancer therapy to NCI CTC (Version 5.0) Grade ≤ 1 or to the baseline laboratory values as defined in Inclusion Criterion Number 10. 10. Adequate hematological profile, renal and hepatic functions. 11. All patients must agree before enrollment to undergo germline BRCA1 and BRCA2 testing on blood. The test will be performed in a centralized laboratory selected by the sponsor. Availability of an ad hoc blood sample is mandatory for central germline BRCA analysis both in dose escalation and in dose expansion. 12. Patients must use effective contraception or abstinence. Female patients of childbearing potential must agree to use effective contraception or abstinence during the period of therapy and in the following 6 months after discontinuation of study treatment. Being NMS-03305293 a potential CYP3A perpetrator, hormonal contraception may lose efficacy while on treatment with NMS-03305293, therefore this should be taken into account. Male patients must be surgically sterile or must agree to use effective contraception or abstinence during the period of therapy and in the following 90 days after discontinuation of study treatment. 13. Capability to swallow capsules intact (without chewing, crushing, or opening). 14. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study indications or procedures.

HER2 negative breast cancer: no more than 3 prior chemotherapy regimens for locally advanced and/or metastatic disease (no limit on prior hormonal therapies or targeted anticancer therapies). At least 1 line of taxane or anthracycline based chemotherapy, if not contraindicated, in adjuvant/neoadjuvant or metastatic setting. If HR (Hormone Receptor) positive, at least 1 line of prior endocrine therapy. Prior treatment with PARP inhibitors is required in the HER2 neg breast cancer cohort pre-treated with a PARP inhibitor
Epithelial ovarian cancer: no more than 4 prior regimens for locally advanced/metastatic disease including at least 1 line of platinum based hemotherapy;
CRPC: no more than 4 prior regimens; must have received at least 1 prior NHA (e.g. abiraterone or enzalutamide) and a taxane. Ongoing androgen deprivation therapy with a GnRH analogue or orchiectomy (i.e., surgical or medical castration) is mandatory.
Pancreatic cancer: no more than 2 prior regimens. Patients may have received prior radiotherapies (not considered as a regimen). 18. Patients with controlled, asymptomatic CNS involvement, which has been stable for the previous 4 weeks, are eligible. The use of seizure prophylaxis is allowed as long as patients are taking non-enzyme-inducing anti-epileptic drugs (non-EIAEDs).

Prior BRCA-associated cancer as long as there is no current evidence of the prior cancer;
Carcinoma in situ or non-melanoma skin cancer;
A cancer diagnosed and definitively treated ≥ 5 years before enrolment with no subsequent evidence of recurrence; 3. Patients with prior platinum therapy exposure who had evidence of disease progression during platinum treatment (refractory disease) and patients whose disease relapsed within 6 months of the last dose of prior adjuvant or neo-adjuvant platinum therapy. 4. Patients who have received prior PARP inhibitors are excluded in the following two cohorts of the Dose Expansion part: HER2 negative breast cancer patients not treated with prior PARP inhibitors and the pancreatic cancer patients cohort. Previous treatment with PARP inhibitors is allowed in the dose escalation part and in the expansion cohorts of ovarian cancer patients and CRPC patients. 5. Patients with known symptomatic brain metastases or leptomeningeal involvement. Patients with asymptomatic brain metastases or leptomeningeal involvement are excluded in the Dose Escalation Part only. 6. Treatment with systemic immune modulators such as corticosteroids at prednisone-equivalent dose of >10 mg/day, cyclosporine and tacrolimus or radiotherapy within 28 days before Cycle 1 Day 1. 7. Prior high-dose chemotherapy with bone marrow or stem cell transplant. 8. Major surgery, other than diagnostic surgery, within 4 weeks prior to treatment. 9. Any of the following in the past 6 months: myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis. 10. Pregnancy or breast-feeding women. 11. Known active infections (bacterial, fungal, viral including HIV positivity). 12. Active gastrointestinal disease (e.g., documented gastrointestinal ulcer, Crohn's disease, ulcerative colitis, or short gut syndrome) or other syndromes that would impact on drug absorption. 13. Patients with QTc interval ≥ 460 milliseconds for women, ≥450 for men or with risk factors for torsade de pointes (e.g., heart failure, uncontrolled hypokalemia, family history of long QT syndrome) or receiving treatment with concomitant medications known to prolong the QT/QTc interval that cannot be replaced with another treatment prior to enrolment. 14. Patients receiving treatment with concomitant medications known to be CYP2D6 and CYP2C19 sensitive substrates that cannot be replaced with another treatment. 15. Other severe acute or chronic medical or psychiatric condition (including history of seizure disorder) or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study or could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

PRINCIPAL_INVESTIGATOR: Valentina Guarneri, MD, Istituto Oncologico Veneto IRCCS

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

PatientS

Caregivers

Clinical Trial Record